Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 11/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NEK9 | Q8TD19 | 1/20 | 0.38 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747807 | 0.90 | PDPK1 (0.44) | PDPK1FGFR1FLT1KDREGFR | |
| SCHEMBL4744181 | 0.79 | PDPK1 (0.46) | PDPK1TYK2ATMNEK9NEK6 | |
| SCHEMBL4747140 | 0.77 | PDPK1 (0.43) | PDPK1KDRTYK2ATMNEK9 | |
| SCHEMBL4745763 | 0.74 | SPIN1 (0.44) | PDPK1 | |
| SCHEMBL7666280 | 0.73 | HSP90AB1 (0.58) | FLT1KDREGFRPGK1DHFR | |
| SCHEMBL30016797 | 0.70 | PDPK1 (0.43) | PDPK1FGFR1FLT1KDRSRC | |
| SCHEMBL4746478 | 0.69 | PDPK1 (0.52) | PDPK1FGFR1FLT1KDREGFR | |
| SCHEMBL24355432 | 0.68 | PDPK1 (0.57) | PDPK1 | |
| SCHEMBL29756065 | 0.68 | PDPK1 (0.57) | PDPK1 | |
| SCHEMBL26069539 | 0.65 | PDPK1 (0.55) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008109599-A1 | PYRIMIDO [5,4-C] QUINOLINE-2, 4-DIAMINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | DCK, PDK4, PDK2 | PDPK1 6/4885FGFR1 809/4885FLT1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.